Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

Cancer research - 15 May 2011

LaBonte Melissa J, Wilson Peter M, Fazzone Will, Russell Jared, Louie Stan G, El-Khoueiry Anthony, Lenz Heinz-Josef, Ladner Robert D

Abstract excerpt

As key molecules that drive progression and chemoresistance in gastrointestinal cancers, epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in this setting. Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways. Histone deacetylase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors
Share to Hydroxamic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lapatinib

Share to Mice, Inbred BALB C

Share to Neoplasm Transplantation

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 21464044
DOI: 10.1158/0008-5472.CAN-10-2430
PMCID: PMC3118510

Genes

EGFR
KRAS
BRAF
CCND1
IRAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.PMID 21464044Read ↗

Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell deathSemantic proximity Read ↗

Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future ConsiderationsSemantic proximity Read ↗

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell DeathSemantic proximity Read ↗

CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal modelSemantic proximity Read ↗

Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growthSemantic proximity Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read ↗

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer ActivitySemantic proximity Read ↗

Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell LinesSemantic proximity Read ↗

Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivoSemantic proximity Read ↗

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic CancerSemantic proximity Read ↗

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.